Adenoid cystic carcinoma (ACC) is a rare malignancy of the secretory glands with a high tendency to invade adjacent tissue and spread to the lung, bone or liver. No treatments other than surgery or radiotherapy are available, so new therapeutic strategies are urgently needed.
Researchers from the University of Pittsburgh School of Medicine have linked pulmonary arterial hypertension (PAH), a progressive disease characterized by blood vessel remodeling, with lysosomal dysfunction and sterol metabolism. They reported their results on Jan. 23, 2025, in Science.
A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.
Ohio State University has described NADH-ubiquinone oxidoreductase (complex I) inhibitors acting as radiosensitizers for radiation therapy reported to be useful for the treatment of cancer.
Forschungsverbund Berlin eV has divulged phosphatidylinositol 4-phosphate 3-kinase (PI3K) inhibitors, particularly PI3K C2 domain-containing subunit β (PIK3C2B) inhibitors, reported to be useful for the treatment of cancer, diabetes, X-linked myotubular myopathy and cardiovascular disorders.
Shanghaitech University has identified thiazolidinedione compounds acting as DNA methyltransferase 3A (DNMT3A) inhibitors reported to be useful for the treatment of acute myeloid leukemia and overgrowth syndrome.
Hangzhou Healthytide Biotechnology Co. Ltd. has synthesized peptoid compounds targeting integrin α5β1 and/or integrin αvβ5 and/or αvβ6 reported to be useful for the diagnosis and treatment of cancer.
Melanoma is responsible for about 80% of skin cancer deaths worldwide, particularly in cases with metastasis. Melanoma shows resistance to standard therapy and the search for novel treatment options is a medical need.
Researchers from Wenzhou Medical University and affiliated organizations presented the discovery and preclinical characterization of a novel myeloid differentiation primary response 88 (MyD88) inhibitor for the treatment of acute lung injury (ALI).
RSS
